Delivering the Goods for Genome Engineering and Editing

Human Gene Therapy

Volumn 26, Issue 8, 2015, Pages 486-497

  Skipper, Kristian Alsbjerg ^a   Mikkelsen, Jacob Giehm ^a  

^a AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMID DNA; RECOMBINANT PROTEIN; RNA; RESTRICTION ENDONUCLEASE;

DNA TRANSPOSITION; ENZYME SYNTHESIS; GENE DELIVERY SYSTEM; GENETIC ENGINEERING; GENOME EDITING; HOMOLOGOUS RECOMBINATION; HUMAN; IN VITRO GENE TRANSFER; LENTIVIRINAE; MODIFIER GENE; NONHUMAN; PROTEIN TRANSPORT; REVIEW; VIRAL GENE DELIVERY SYSTEM; ANIMAL; GENE THERAPY; GENE VECTOR; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; GENETICS; HUMAN GENOME; PROCEDURES;

BACTERIA (MICROORGANISMS);

ANIMALS; DNA RESTRICTION-MODIFICATION ENZYMES; GENETIC THERAPY; GENETIC VECTORS; GENOME, HUMAN; HUMANS; LENTIVIRUS; TRANSDUCTION, GENETIC; TRANSFECTION;

EID: 84939802888     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2015.063     Document Type: Review

References (116)

1. Craigie R, Bushman FD. HIV DNA integration. Cold Spring Harb Perspect Med 2012;2: a006890.
2. JinekM, Chylinski K, Fonfara I, et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 2012;337:816-821.
3. Wiedenheft B, Sternberg SH, Doudna JA. RNAguided genetic silencing systems in bacteria and archaea. Nature 2012;482:331-338.
4. Jacquier A, Dujon B. An intron-encoded protein is active in a gene conversion process that spreads an intron into a mitochondrial gene. Cell 1985;41:383-394.
5. Porteus MH, Baltimore D. Chimeric nucleases stimulate gene targeting in human cells. Science 2003;300:763.
6. Christian M, Cermak T, Doyle EL, et al. Targeting DNA double-strand breaks with TAL effector nucleases. Genetics 2010;186:757-761.
7. Miller JC, Tan S, Qiao G, et al. A TALE nuclease architecture for efficient genome editing. Nat Biotechnol 2011;29:143-148.
8. Abremski K, Hoess R, Sternberg N. Studies on the properties of P1 site-specific recombination: evidence for topologically unlinked products following recombination. Cell 1983;32:1301-1311.
9. Sternberg N, Hamilton D. Bacteriophage P1 sitespecific recombination. I. Recombination between loxP sites. J Mol Biol 1981;150:467-486.
10. Babineau D, Vetter D, Andrews BJ, et al. The FLP protein of the 2-micron plasmid of yeast. Purification of the protein from Escherichia coli cells expressing the cloned FLP gene. J Biol Chem 1985;260:12313-12319.
11. Meyer-Leon L, Senecoff JF, Bruckner RC, et al. Sitespecific genetic recombination promoted by the FLP protein of the yeast 2-micron plasmid in vitro. Cold Spring Harb Symp Quant Biol 1984;49:797-804.
12. Vetter D, Andrews BJ, Roberts-Beatty L, et al. Sitespecific recombination of yeast 2-micron DNA in vitro. ProcNatlAcadSci USA 1983;80:7284-7288.
13. Olivares EC, Hollis RP, Chalberg TW, et al. Sitespecific genomic integration produces therapeutic Factor IX levels in mice. Nat Biotechnol 2002;20:1124-1128.
14. Ivics Z, Hackett PB, Plasterk RH, et al. Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells. Cell 1997;91:501-510.
15. Skipper KA, Andersen PR, Sharma N, et al. DNA transposon-based gene vehicles-scenes from an evolutionary drive. J Biomed Sci 2013;20:92.
16. Di Matteo M, Matrai J, Belay E, et al. PiggyBac toolbox. Methods Mol Biol 2012;859:241-254.
17. Ivics Z, Izsvak Z. Nonviral gene delivery with the sleeping beauty transposon system. Hum Gene Ther 2011;22:1043-1051.
18. Hsu PD, Lander ES, Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. Cell 2014;157:1262-1278.
19. Mussolino C, Cathomen T. TALE nucleases: tailored genome engineering made easy. Curr Opin Biotechnol 2012;23:644-650.
20. Wirt SE, Porteus MH. Development of nucleasemediated site-specific genome modification. Curr Opin Immunol 2012;24:609-616.
21. Graham FL, van der Eb AJ. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 1973;52:456-467.
22. Maasho K, Marusina A, Reynolds NM, et al. Efficient gene transfer into the human natural killer cell line, NKL, using the Amaxa nucleofection system. J Immunol Methods 2004;284:133-140.
23. Ewert KK, Zidovska A, Ahmad A, et al. Cationic liposome-nucleic acid complexes for gene delivery and silencing: pathways and mechanisms for plasmid DNA and siRNA. Top Curr Chem 2010;296:191-226.
24. Kang HC, Huh KM, Bae YH. Polymeric nucleic acid carriers: current issues and novel design approaches. J Control Release 2012;164:256-264.
25. Ding S, Wu X, Li G, et al. Efficient transposition of the piggyBac (PB) transposon in mammalian cells and mice. Cell 2005;122:473-483.
26. Kebriaei P, Huls H, Jena B, et al. Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stemcell transplantation for advanced B-lymphoid malignancies. Hum Gene Ther 2012;23:444-450.
27. Woltjen K, Michael IP, Mohseni P, et al. piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature 2009;458:766-770.
28. Grabundzija I, Wang J, Sebe A, et al. Sleeping Beauty transposon-based system for cellular reprogramming and targeted gene insertion in induced pluripotent stem cells. Nucleic Acids Res 2013;41:1829-1847.
29. Muenthaisong S, Ujhelly O, Polgar Z, et al. Generation of mouse induced pluripotent stem cells from different genetic backgrounds using Sleeping beauty transposon mediated gene transfer. Exp Cell Res 2012;318:2482-2489.
30. Urnov FD, Miller JC, Lee YL, et al. Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature 2005;435:646-651.
31. Cermak T, Doyle EL, Christian M, et al. Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting. Nucleic Acids Res 2011;39:e82.
32. Cho SW, Kim S, Kim JM, et al. Targeted genome engineeringinhumancellswith theCas9RNA-guided endonuclease. Nat Biotechnol 2013;31:230-232.
33. Jinek M, East A, Cheng A, et al. RNA-programmed genome editing in human cells. Elife 2013;2:e00471.
34. Mali P, Yang L, Esvelt KM, et al. RNA-guided human genome engineering via Cas9. Science 2013;339:823-826.
35. Sun N, Zhao H. Seamless correction of the sickle cell disease mutation of the HBB gene in human induced pluripotent stem cells using TALENs. Biotechnol Bioeng 2014;111:1048-1053.
36. Xie F, Ye L, Chang JC, et al. Seamless gene correction of beta-thalassemia mutations in patient-specific iPSCs using CRISPR/Cas9 and piggyBac. Genome Res 2014;24:1526-1533.
37. Ye L, Wang J, Beyer AI, et al. Seamless modification of wild-type induced pluripotent stem cells to the natural CCR5Delta32 mutation confers resistance to HIV infection. Proc Natl Acad Sci USA 2014;111:9591-9596.
38. Yusa K, Rashid ST, Strick-Marchand H, et al. Targeted gene correction of alpha1-antitrypsin deficiency in induced pluripotent stem cells. Nature 2011;478:391-394.
39. Moldt B, Yant SR, Andersen PR, et al. Cis-acting gene regulatory activities in the terminal regions of sleeping beauty DNA transposon-based vectors. Hum Gene Ther 2007;18:1193-1204.
40. Walisko O, Ivics Z. Interference with cell cycle progression by parasitic genetic elements: sleeping beauty joins the club. Cell Cycle 2006;5:1275-1280.
41. Walisko O, Izsvak Z, Szabo K, et al. Sleeping Beauty transposase modulates cell-cycle progression through interaction with Miz-1. Proc Natl Acad Sci USA 2006;103:4062-4067.
42. Ehrhardt A, Engler JA, Xu H, et al. Molecular analysis of chromosomal rearrangements in mammalian cells after phiC31-mediated integration. Hum Gene Ther 2006;17:1077-1094.
43. Liu J, Skjorringe T, Gjetting T, et al. PhiC31 integrase induces a DNA damage response and chromosomal rearrangements in human adult fibroblasts. BMC Biotechnol 2009;9:31.
44. Jakobsen JE, Li J, Kragh PM, et al. Pig transgenesis by Sleeping Beauty DNA transposition. Transgenic Res 2011;20:533-545.
45. Staunstrup NH, Madsen J, Primo MN, et al. Development of transgenic cloned pig models of skin inflammation by DNA transposon-directed ectopic expression of human beta1 and alpha2 integrin. PLoS One 2012;7:e36658.
46. Sharma N, Cai Y, Bak RO, et al. Efficient sleeping beauty DNA transposition from DNA minicircles. Mol Ther Nucleic Acids 2013;2:e74.
47. Cai Y, Bak RO, Krogh LB, et al. DNA transposition by protein transduction of the piggyBac transposase from lentiviral Gag precursors. Nucleic Acids Res 2014;42:e28.
48. Liu F, Song Y, Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther 1999;6:1258-1266.
49. Zhang G, Budker V, Wolff JA. High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. Hum Gene Ther 1999;10:1735-1737.
50. Yant SR, Meuse L, Chiu W, et al. Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA transposon system. Nat Genet 2000;25:35-41.
51. Mikkelsen JG, Yant SR, Meuse L, et al. Helper-Independent Sleeping Beauty transposontransposase vectors for efficient nonviral gene delivery and persistent gene expression in vivo. Mol Ther 2003;8:654-665.
52. Ohlfest JR, Frandsen JL, Fritz S, et al. Phenotypic correction and long-term expression of factor VIII in hemophilic mice by immunotolerization and nonviral gene transfer using the Sleeping Beauty transposon system. Blood 2005;105:2691-2698.
53. Aronovich EL, Bell JB, Belur LR, et al. Prolonged expression of a lysosomal enzyme in mouse liver after Sleeping Beauty transposon-mediated gene delivery: implications for non-viral gene therapy of mucopolysaccharidoses. J Gene Med 2007;9: 403-415.
54. Montini E, Held PK, Noll M, et al. In vivo correction of murine tyrosinemia type I by DNA-mediated transposition. Mol Ther 2002;6:759-769.
55. Nakanishi H, Higuchi Y, Kawakami S, et al. piggyBac transposon-mediated long-term gene expression in mice. Mol Ther 2010;18:707-714.
56. Doherty JE, Huye LE, Yusa K, et al. Hyperactive piggyBac gene transfer in human cells and in vivo. Hum Gene Ther 2012;23:311-320.
57. Mates L, Chuah MK, Belay E, et al. Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates. Nat Genet 2009;41:753-761.
58. Xue W, Chen S, Yin H, et al. CRISPR-mediated direct mutation of cancer genes in the mouse liver. Nature 2014;514:380-384.
59. Yin H, Xue W, Chen S, et al. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat Biotechnol 2014;32:551-553.
60. Wilber A, Frandsen JL, Geurts JL, et al. RNA as a source of transposase for sleeping beautymediated gene insertion and expression in somatic cells and tissues. Mol Ther 2006;13:625-630.
61. Wilber A, Wangensteen KJ, Chen Y, et al. Messenger RNA as a source of transposase for Sleeping Beauty transposon-mediated correction of hereditary tyrosinemia type I. Mol Ther 2007; 5:1280-1287.
62. Bire S, Gosset D, Jegot G, et al. Exogenous mRNA delivery and bioavailability in gene transfer mediated by piggyBac transposition. BMC Biotechnol 2013;13:75.
63. Genovese P, Schiroli G, Escobar G, et al. Targeted genome editing in human repopulating haematopoietic stem cells. Nature 2014;510:235-240.
64. Jin Z,Maiti S, Huls H, et al. The hyperactive Sleeping Beauty transposase SB100X improves the genetic modification of T cells to express a chimeric antigen receptor. Gene Ther 2011;18:849-856.
65. Singh H,Moyes JS, HulsMH, et al.Manufacture of T cells using the Sleeping Beauty systemto enforce expression of a CD19-specific chimeric antigen receptor. Cancer Gene Ther 2015;22:95-100.
66. Kay MA. State-of-the-art gene-based therapies: the road ahead. Nat Rev Genet 2011;12:316-328.
67. Yant SR, Ehrhardt A, Mikkelsen JG, et al. Transposition from a gutless adeno-transposon vector stabilizes transgene expression in vivo. Nat Biotechnol 2002;20:999-1005.
68. Hausl MA, Zhang W, Muther N, et al. Hyperactive sleeping beauty transposase enables persistent phenotypic correction in mice and a canine model for hemophilia B. Mol Ther 2010;18:1896-1906.
69. Rio P, Banos R, Lombardo A, et al. Targeted gene therapy and cell reprogramming in Fanconi anemia. EMBO Mol Med 2014;6:835-848.
70. Holkers M, Maggio I, Liu J, et al. Differential integrity of TALE nuclease genes following adenoviral and lentiviral vector gene transfer into human cells. Nucleic Acids Res 2013;41:e63.
71. Anguela XM, Sharma R, Doyon Y, et al. Robust ZFN-mediated genome editing in adult hemophilic mice. Blood 2013;122:3283-3287.
72. Li H, Haurigot V, Doyon Y, et al. In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature 2011;475:217-221.
73. Ran FA, Cong L, Yan WX, et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature 2015;520:186-191.
74. Ding Q, Strong A, Patel KM, et al. Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing. Circ Res 2014;115:488-492.
75. Zhang W, SolankiM,Muther N, et al. Hybrid adenoassociated viral vectors utilizing transposasemediated somatic integration for stable transgene expression in human cells. PLoS One 2013;8: e76771.
76. Cooney AL, Singh BK, Sinn PL. Hybrid nonviral/viral vector systems for improved piggyBac DNA transposon in vivo delivery. Mol Ther 2015;23:667-674.
77. Cunningham SC, Siew SM, Hallwirth CV, et al. Modeling correction of severe urea cycle defects in the growing murine liver using a hybrid rAAV/ piggyBac transposase gene delivery system. Hepatology 2015;62:417-428.
78. de Silva S, Bowers WJ. Targeting the central nervous system with herpes simplex virus/ Sleeping Beauty hybrid amplicon vectors. Curr Gene Ther 2011;11:332-340.
79. Wanisch K, Yanez-Munoz RJ. Integration-deficient lentiviral vectors: a slow coming of age. Mol Ther 2009;17:1316-1332.
80. Moldt B, Staunstrup NH, Jakobsen M, et al. Genomic insertion of lentiviral DNA circles directed by the yeast Flp recombinase. BMC Biotechnol 2008;8:60.
81. Staunstrup NH, Moldt B, Mates L, et al. Hybrid lentivirus-transposon vectors with a random integration profile in human cells. Mol Ther 2009;17: 1205-1214.
82. Vink CA, Gaspar HB, Gabriel R, et al. Sleeping beauty transposition from nonintegrating lentivirus. Mol Ther 2009;17:1197-1204.
83. Holkers M, Maggio I, Henriques SF, et al. Adenoviral vector DNA for accurate genome editing with engineered nucleases. Nat Methods 2014;11: 1051-1057.
84. Sanjana NE, Shalem O, Zhang F. Improved vectors and genome-wide libraries for CRISPR screening. Nat Methods 2014;11:783-784.
85. Shalem O, Sanjana NE, Hartenian E, et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 2014;343:84-87.
86. Bechara C, Sagan S. Cell-penetrating peptides: 20 years later, where do we stand? FEBS Lett 2013;587:1693-1702.
87. Lee CY, Li JF, Liou JS, et al. A gene delivery system for human cells mediated by both a cellpenetrating peptide and a piggyBac transposase. Biomaterials 2011;32:6264-6276.
88. Järver P, Fernaeus S, El-Andaloussi S, et al. Cotransduction of sleeping beauty transposase and donor plasmid via a cell-penetrating peptide: a simple one step method. Int J Peptide Res Ther. 2008;14:58-63.
89. Mellert K, Lamla M, Scheffzek K, et al. Enhancing endosomal escape of transduced proteins by photochemical internalisation. PLoS One 2012; 7:e52473.
90. Gaj T, Guo J, Kato Y, et al. Targeted gene knockout by direct delivery of zinc-finger nuclease proteins. Nat Methods 2012;9:805-807.
91. Ramakrishna S, Kwaku Dad AB, Beloor J, et al. Gene disruption by cell-penetrating peptide-mediated delivery of Cas9 protein and guide RNA. Genome Res 2014;24:1020-1027.
92. Kim S, Kim D, Cho SW, et al. Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. Genome Res 2014;24:1012-1019.
93. McDonald D, Vodicka MA, Lucero G, et al. Visualization of the intracellular behavior of HIV in living cells. J Cell Biol 2002;159:441-452.
94. Wu X, Liu H, Xiao H, et al. Targeting foreign proteins to human immunodeficiency virus particles via fusion with Vpr and Vpx. J Virol 1995;69:3389-3398.
95. Swanson CM, Malim MH. SnapShot: HIV-1 proteins. Cell 2008;133:742, 742.e1.
96. Izmiryan A, Basmaciogullari S, Henry A, et al. Efficient gene targeting mediated by a lentiviral vector-associated meganuclease. Nucleic Acids Res 2011;39:7610-7619.
97. Michel G, Yu Y, Chang T, et al. Site-specific gene insertion mediated by a Cre-loxP-carrying lentiviral vector. Mol Ther 2010;18:1814-1821.
98. Cai Y, Mikkelsen JG. Driving DNA transposition by lentiviral protein transduction. Mob Genet Elements 2014;4:e29591.
99. Tachiwana H, Shimura M, Nakai-Murakami C, et al. HIV-1 Vpr induces DNA double-strand breaks. Cancer Res 2006;66:627-631.
100. Jones TA, Blaug G, Hansen M, et al. Assembly of gag-beta-galactosidase proteins into retrovirus particles. J Virol 1990;64:2265-2279.
101. Weldon RA Jr., Erdie CR, Oliver MG, et al. Incorporation of chimeric gag protein into retroviral particles. J Virol 1990;64:4169-4179.
102. Voelkel C, Galla M, Maetzig T, et al. Protein transduction from retroviral Gag precursors. Proc Natl Acad Sci USA 2010;107:7805-7810.
103. Aoki T, Miyauchi K, Urano E, et al. Protein transduction by pseudotyped lentivirus-like nanoparticles. Gene Ther 2011;18:936-941.
104. Miyauchi K, Urano E, Takizawa M, et al. Therapeutic potential of HIV protease-activable CASP3. Sci Rep 2012;2:359.
105. Jouvenet N, Bieniasz PD, Simon SM. Imaging the biogenesis of individual HIV-1 virions in live cells. Nature 2008;454:236-240.
106. Larson DR, Johnson MC, Webb WW, et al. Visualization of retrovirus budding with correlated light and electron microscopy. Proc Natl Acad Sci USA 2005;102:15453-15458.
107. Larson DR, Ma YM, Vogt VM, et al. Direct measurement of Gag-Gag interaction during retrovirus assembly with FRET and fluorescence correlation spectroscopy. J Cell Biol 2003;162:1233-1244.
108. Li H, Dou J, Ding L, et al. Myristoylation is required for human immunodeficiency virus type 1 Gag-Gag multimerization in mammalian cells. J Virol 2007;81:12899-12910.
109. Muller B, Daecke J, Fackler OT, et al. Construction and characterization of a fluorescently labeled infectious human immunodeficiency virus type 1 derivative. J Virol 2004;78:10803-10813.
110. Schenkwein D, Turkki V, Karkkainen HR, et al. Production of HIV-1 integrase fusion proteincarrying lentiviral vectors for gene therapy and protein transduction. Hum Gene Ther 2010; 21:589-602.
111. Schenkwein D, Turkki V, Ahlroth MK, et al. rDNA-directed integration by an HIV-1 integrase-I-PpoI fusion protein. Nucleic Acids Res 2013; 41:e61.
112. Turkki V, Schenkwein D, Timonen O, et al. Lentiviral protein transduction with genome-modifying HIV-1 integrase-I-PpoI fusion proteins: studies on specificity and cytotoxicity. Biomed Res Int 2014;2014: 379340.
113. Yusa K, Zhou L, Li MA, et al. A hyperactive piggyBac transposase for mammalian applications. Proc Natl Acad Sci USA 2011;108:1531-1536.
114. Cai Y, Bak RO, Mikkelsen JG. Targeted genome editing by lentiviral protein transduction of zincfinger and TAL-effector nucleases. Elife 2014;3: e01911.
115. Flotte TR. Therapeutic germ line alteration: has CRISPR/Cas9 technology forced the question? Hum Gene Ther 2015;26:245-246.
116. Holopainen T, HietalaM. Nightwish. Endless forms most beautiful. Nuclear Blast/Roadrunner, 2015.